[1]
McLean M.J., Schmutz M., Wamil A.W., et al.: Oxcarbazepine:
mechanisms of action. Epilepsia, 1994;35:5-9.
[1]
McLean M.J., Schmutz M., Wamil A.W., et al.: Oxcarbazepine:
mechanisms of action. Epilepsia, 1994;35:5-9.
[2]
Patsalos P.N., Elyas A.A., Zakrzewska J.M.: Protein binding of
oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine,
in patients with trigeminal neuralgia. Eur J Clin Pharmacol, 1990;39:
413-415.
[2]
Patsalos P.N., Elyas A.A., Zakrzewska J.M.: Protein binding of
oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine,
in patients with trigeminal neuralgia. Eur J Clin Pharmacol, 1990;39:
413-415.
[3]
Flesch G.: Overview of the clinical pharmacokinetics of oxcarbazepine.
Clin Drug Investig, 2004;24:185-203.
[3]
Flesch G.: Overview of the clinical pharmacokinetics of oxcarbazepine.
Clin Drug Investig, 2004;24:185-203.
[4]
Gonzalez-Esquivel D.F., Ortega-Gavilan M., Alcantara-Lopez G., et al.:
Plasma level monitoring of oxcarbazepine in epileptic patients. Arch Med
Res, 2000;31:202-205.
[4]
Gonzalez-Esquivel D.F., Ortega-Gavilan M., Alcantara-Lopez G., et al.:
Plasma level monitoring of oxcarbazepine in epileptic patients. Arch Med
Res, 2000;31:202-205.
[5]
Keranen T., Jolkkonen J., Jensen P.K., et al.: Absence of interaction
between oxcarbazepine and erythromycin. Acta Neurol Scand, 1992;
86:120-123.
[5]
Keranen T., Jolkkonen J., Jensen P.K., et al.: Absence of interaction
between oxcarbazepine and erythromycin. Acta Neurol Scand, 1992;
86:120-123.
[6]
Keranen T., Jolkkonen J., Klosterskov-Jensen P., et al.: Oxcarbazepine
does not interact with cimetidine in healthy volunteers. Acta Neurol
Scand, 199;85:239-242.
[6]
Keranen T., Jolkkonen J., Klosterskov-Jensen P., et al.: Oxcarbazepine
does not interact with cimetidine in healthy volunteers. Acta Neurol
Scand, 199;85:239-242.
[7]
Adin J., Arteaga R., Herranz J.L., et al.: The use of intravenous valproate.
Rev Neurol, 1999;29:744-753.
[7]
Adin J., Arteaga R., Herranz J.L., et al.: The use of intravenous valproate.
Rev Neurol, 1999;29:744-753.
[8]
Baruzzi A., Albani F., Riva R.: Oxcarbazepine: pharmacokinetic
interactions and their clinical relevance. Epilepsia, 1994;35:14-19.
[8]
Baruzzi A., Albani F., Riva R.: Oxcarbazepine: pharmacokinetic
interactions and their clinical relevance. Epilepsia, 1994;35:14-19.
[9]
Sallas W.M., Milosavljev S., D’Souza J., et al.: Pharmacokinetic drug
interactions in children taking oxcarbazepine. Clin Pharmacol Ther, 2003;
74:138-149.
[9]
Sallas W.M., Milosavljev S., D’Souza J., et al.: Pharmacokinetic drug
interactions in children taking oxcarbazepine. Clin Pharmacol Ther, 2003;
74:138-149.
[10]
Reinikainen K.J., Keranen T., Halonen T., et al.: Comparison of
oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res,
1987;1:284-289.
[10]
Reinikainen K.J., Keranen T., Halonen T., et al.: Comparison of
oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res,
1987;1:284-289.
[11]
Glauser T.A.: Oxcarbazepine in the treatment of epilepsy.
Pharmacotherapy, 2001;21:904-919
[11]
Glauser T.A.: Oxcarbazepine in the treatment of epilepsy.
Pharmacotherapy, 2001;21:904-919
[12]
Barcs G., Walker E.B., Elger C.E., et al.: Oxcarbazepine placebocontrolled,
dose-ranging trial in refractory partial epilepsy. Epilepsia,
2000;41:1597-1607.
[12]
Barcs G., Walker E.B., Elger C.E., et al.: Oxcarbazepine placebocontrolled,
dose-ranging trial in refractory partial epilepsy. Epilepsia,
2000;41:1597-1607.
[13]
Glauser T.A., Nigro M., Sachdeo R., et al.: Adjunctive therapy with
oxcarbazepine in children with partial seizures. The Oxcarbazepine
Pediatric Study Group. Neurology, 2000;54:2237-2244.
[13]
Glauser T.A., Nigro M., Sachdeo R., et al.: Adjunctive therapy with
oxcarbazepine in children with partial seizures. The Oxcarbazepine
Pediatric Study Group. Neurology, 2000;54:2237-2244.
[14]
Pina-Garza J.E., Espinoza R., Nordli D.: Oxcarbazepine adjunctive therapy
in infants and young children with partial seizures. Neurology, 2005;65;
1370-1375.
[14]
Pina-Garza J.E., Espinoza R., Nordli D.: Oxcarbazepine adjunctive therapy
in infants and young children with partial seizures. Neurology, 2005;65;
1370-1375.
[15]
Dam M., Ekberg R., Loyning Y., et al.: A double-blind study comparing
oxcarbazepine and carbamazepine in patients with newly diagnosed,
previously untreated epilepsy. Epilepsy Res, 1989;3:70-76.
[15]
Dam M., Ekberg R., Loyning Y., et al.: A double-blind study comparing
oxcarbazepine and carbamazepine in patients with newly diagnosed,
previously untreated epilepsy. Epilepsy Res, 1989;3:70-76.
[16]
Bill P.A., Vigonius U., Pohlmann H., Guerreiro C.A., et al.: A double-blind
controlled clinical trial of oxcarbazepine versus phenytoin in adults with
previously untreated epilepsy. Epilepsy Res, 1997;27:195-204.
[16]
Bill P.A., Vigonius U., Pohlmann H., Guerreiro C.A., et al.: A double-blind
controlled clinical trial of oxcarbazepine versus phenytoin in adults with
previously untreated epilepsy. Epilepsy Res, 1997;27:195-204.
[17]
Guerreiro M.M., Vigonius U., Pohlmann H., et al: A double-blind
controlled clinical trial of oxcarbazepine versus phenytoin in children and
adolescents with epilepsy. Epilepsy Res, 1997;27:205-213.
[17]
Guerreiro M.M., Vigonius U., Pohlmann H., et al: A double-blind
controlled clinical trial of oxcarbazepine versus phenytoin in children and
adolescents with epilepsy. Epilepsy Res, 1997;27:205-213.
[18]
Christe W., Kramer G., Vigonius U., et al.: A double-blind controlled
clinical trial: oxcarbazepine versus sodium valproate in adults with newly
diagnosed epilepsy. Epilepsy Res, 1997;26:451-460.
[18]
Christe W., Kramer G., Vigonius U., et al.: A double-blind controlled
clinical trial: oxcarbazepine versus sodium valproate in adults with newly
diagnosed epilepsy. Epilepsy Res, 1997;26:451-460.
[19]
Gaily E., Granstrom M.L. i Liukkonen E.: Oxcarbazepine in the treatment
of early childhood epilepsy. J Child Neurol, 1997;12:496-498.
[19]
Gaily E., Granstrom M.L. i Liukkonen E.: Oxcarbazepine in the treatment
of early childhood epilepsy. J Child Neurol, 1997;12:496-498.
[20]
Korn-Merker E., Holtmann M. Krause M.: Oxcarbazepine: experiences in
142children and adolescents with difficult-to-treat epilepsies [abstract].
Epilepsia, 2001;42 (Suppl 7): 181.
[20]
Korn-Merker E., Holtmann M. Krause M.: Oxcarbazepine: experiences in
142children and adolescents with difficult-to-treat epilepsies [abstract].
Epilepsia, 2001;42 (Suppl 7): 181.
[21]
Mandelbaum D., Kugler S.: Efficacy of oxcarbazepine in the treatment
of children with partial seizures [abstract]. Epilepsia, 2000;41(Suppl 7):
185-186.
[21]
Mandelbaum D., Kugler S.: Efficacy of oxcarbazepine in the treatment
of children with partial seizures [abstract]. Epilepsia, 2000;41(Suppl 7):
185-186.
[22]
Kothare S.V., Mohsem B., Melvin J.J., et al.: Oxcarbazepine monothapy
in children and adolescents: a single-center clinical experience. Pediatr
Neurol, 2006;35:235-239.
[22]
Kothare S.V., Mohsem B., Melvin J.J., et al.: Oxcarbazepine monothapy
in children and adolescents: a single-center clinical experience. Pediatr
Neurol, 2006;35:235-239.
[23]
Kothare S.V., Mostofi N., Khurana D.S., et al.: Oxcarbazepine therapy in
very young children: a single-center clinical experience. Pediatr Neurol,
2006;35:173-176.
[23]
Kothare S.V., Mostofi N., Khurana D.S., et al.: Oxcarbazepine therapy in
very young children: a single-center clinical experience. Pediatr Neurol,
2006;35:173-176.
[24]
Coppola G., Franzoni E., Verrotti A., et al.: Levetiracetam or oxcarbazepine
as monotherapy in newly diagnosed benign epilepsy of childhood with
centrotemporal spikes (BECTS): an open-label, parallel group trial. Brain
Dev, 2007;29:281-284.
[24]
Coppola G., Franzoni E., Verrotti A., et al.: Levetiracetam or oxcarbazepine
as monotherapy in newly diagnosed benign epilepsy of childhood with
centrotemporal spikes (BECTS): an open-label, parallel group trial. Brain
Dev, 2007;29:281-284.
[25]
Gaily E., Granstrom M.L. i Liukkonen E.: Oxcarbazepine in the treatment
of epilepsy in children and adolescents with intellectual disability. J
Intell. Disability Research 199;42:41-45.
[25]
Gaily E., Granstrom M.L. i Liukkonen E.: Oxcarbazepine in the treatment
of epilepsy in children and adolescents with intellectual disability. J
Intell. Disability Research 199;42:41-45.
[26]
Franzoni E., Garone C., Sarajlija J., et al.: Open prospective study on
oxcarbazepine in epilepsy in children: A preliminary report, Seizure;
2006;15:292-298.
[26]
Franzoni E., Garone C., Sarajlija J., et al.: Open prospective study on
oxcarbazepine in epilepsy in children: A preliminary report, Seizure;
2006;15:292-298.
[27]
Franzoni E.: Prospective study on treatment of oxcarbazepine in pediatric
epilepsy. J. Neurol, 2009;256:1527-1532.
[27]
Franzoni E.: Prospective study on treatment of oxcarbazepine in pediatric
epilepsy. J. Neurol, 2009;256:1527-1532.
[28]
Ferraro D., Daraio S., Solis P.: Oxcarbazepine in early childhood [abstract].
Epilepsia, 1997;38(Suppl 8):96.
[28]
Ferraro D., Daraio S., Solis P.: Oxcarbazepine in early childhood [abstract].
Epilepsia, 1997;38(Suppl 8):96.
[29]
Jędrzejczak J., Zwoliński, P.: [Red.]. Nowe leki przeciwpadaczkowe.
2000, Fundacja Epileptologii: Warszawa.
[29]
Jędrzejczak J., Zwoliński, P.: [Red.]. Nowe leki przeciwpadaczkowe.
2000, Fundacja Epileptologii: Warszawa.
[30]
Dong X., Leppik I.E., White J., et al.: Hyponatremia from oxcarbazepine
and carbamazepine. Neurology, 2005;65:1976-1978.
[30]
Dong X., Leppik I.E., White J., et al.: Hyponatremia from oxcarbazepine
and carbamazepine. Neurology, 2005;65:1976-1978.
[31]
Van Amelsvoort T., Bakshi R., Devaux C.B., et al.: Hyponatremia
associated with carbamazepine and oxcarbazepine therapy: a review.
Epilepsia, 1994;35:181-188.
[31]
Van Amelsvoort T., Bakshi R., Devaux C.B., et al.: Hyponatremia
associated with carbamazepine and oxcarbazepine therapy: a review.
Epilepsia, 1994;35:181-188.
[32]
Aikia M., Kalviainen R., Sivenius J., et al.: Cognitive effects of
oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy:
one year follow-up. Epilepsy Res, 1992;11:199-203.
[32]
Aikia M., Kalviainen R., Sivenius J., et al.: Cognitive effects of
oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy:
one year follow-up. Epilepsy Res, 1992;11:199-203.
[33]
Mazurkiewicz-Bełdzińska M., Olszewska A.: Wpływ karbamazepiny,
fenytiony i okskarbazepiny na funkcje poznawcze u dzieci z padaczką.
Epileptologia, 2000;8:35-46.
[33]
Mazurkiewicz-Bełdzińska M., Olszewska A.: Wpływ karbamazepiny,
fenytiony i okskarbazepiny na funkcje poznawcze u dzieci z padaczką.
Epileptologia, 2000;8:35-46.
[34]
Northam R.S., Hernandez A.W., Litzinger M.J., et al.: Oxcarbazepine in
infants and young children with partial seizures. Pediatr Neurol, 2005;
33:337-344.
[34]
Northam R.S., Hernandez A.W., Litzinger M.J., et al.: Oxcarbazepine in
infants and young children with partial seizures. Pediatr Neurol, 2005;
33:337-344.
[35]
Schmidt D., Arroyo S., Baulac M., et al.: Recommendations on the
clinical use of oxcarbazepine in the treatment of epilepsy: a consensus
view. Acta Neurol Scand, 2001;104:167-170.
[35]
Schmidt D., Arroyo S., Baulac M., et al.: Recommendations on the
clinical use of oxcarbazepine in the treatment of epilepsy: a consensus
view. Acta Neurol Scand, 2001;104:167-170.
[36]
Seneviratne U., D’Souza W., Cook M.: Long-term assessment of
oxcarbazepine in a naturalistic setting: a retrospective study. Acta
Neurol Scand, 2008;117:367-369.
[36]
Seneviratne U., D’Souza W., Cook M.: Long-term assessment of
oxcarbazepine in a naturalistic setting: a retrospective study. Acta
Neurol Scand, 2008;117:367-369.
Scholar Google
PubMed